98%
921
2 minutes
20
Introduction: The hippocampus atrophies with age and is implicated in neurodegenerative disorders including Alzheimer's disease (AD). We examined the interplay between age and apolipoprotein E () genotype on total hippocampal volume.
Methods: Using neuroimaging data from 37,463 UK Biobank participants, we applied linear regression to quantify the association of age and with hippocampal volume and identified the age when volumes of ε2/ε3, ε3/ε4, and ε4/ε4 carriers significantly deviated from ε3/ε3 using generalized additive modeling.
Results: Total hippocampal volume declined with age, with significant differences by genotype emerging after age 60. ε3/ε4 and ε4/ε4 carriers displayed reduced volumes from ages 69 and 61, respectively, while ε2/ε3 showed delayed decline starting at the age of 76.
Discussion: The association of and hippocampal volume is age-dependent, with differences in volumes of ε4/ε4 carriers detected as early as age 61. This work underscores the importance of genotype in determining when to begin screening for AD.
Highlights: Apolipoprotein E () genotype shows an age-dependent association with total hippocampal volume.No association between and total hippocampal volume was detected before age 60.Accelerated decline was observed in ε4/ε4 carriers at age 61 and ε3/ε4 at age 69.Delayed decline was evident in ε2/ε3 carriers starting at age 76.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11567847 | PMC |
http://dx.doi.org/10.1002/dad2.70024 | DOI Listing |
J Am Heart Assoc
September 2025
KHP Centre for Translational Medicine, King's College London British Heart Foundation, Cardiovascular Division, Department of Clinical Pharmacology St Thomas' Hospital London United Kingdom.
Background: The aim of this study was to investigate the associations between pulse pressure (PP) and age-related structural brain changes including brain volumes, white matter hyperintensities (WMH), fractional anisotropy, silent brain lesions, microbleeds, cerebral blood flow and metabolism, and beta-amyloid accumulation.
Methods: Systematic review of PubMed (MEDLINE), Scopus, and Ovid Embase (from inception to January 2023) and references of included studies among adult populations was conducted. Findings were summarized narratively and by performing a fixed-effects meta-analysis.
J Am Heart Assoc
September 2025
Department of Radiology, Beijing Friendship Hospital Capital Medical University Beijing China.
Background: High blood pressure (BP) is a known risk factor for cognitive decline and dementia, but the underlying mechanisms are largely unknown. We investigated the associations of cumulative BP exposure with hippocampal subfield volume and cognitive function and determined whether hippocampal subfield atrophy mediates the association between cumulative BP exposure and cognitive decline.
Methods: Between December 2020 and March 2023, participants were prospectively included from the Kailuan study.
Diabetes Obes Metab
September 2025
Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Aims: Type 2 diabetes (T2D) related cognitive impairment links to comorbid and modifiable olfactory dysfunction; however, the efficacy of olfactory training (OT) to mitigate cognitive decline specifically in these patients with mild cognitive impairment (MCI) remains unestablished. This study aimed to determine whether OT alleviates cognitive decline in this population.
Materials And Methods: In this 16-week, open-label trial, 60 T2D participants with MCI were randomly assigned (1:1) to OT or routine care (control).
Zhongguo Zhong Yao Za Zhi
July 2025
Department of Breast, Beijing University of Chinese Medicine Third Affiliated Hospital Beijing 100029, China.
Study on the mechanism of Fangxia Dihuang Formula(FXDH) in treating breast cancer complicated with depression through the regulation of M1/M2 microglial polarization via the PERK/eIF2α axis. In addition to control group and 4T1 group, a mouse model of breast cancer complicated with depression was established using 4T1 cells combined with corticosterone. The mice were divided into model group, PERK/eIF2α signaling axis agonist(CCT020312, 2 mg·kg~(-1)·d~(-1)) group, CCT020312(2 mg·kg~(-1)·d~(-1)) + FXDH(13.
View Article and Find Full Text PDF